Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice

A. J. M. Beijers; G. Vreugdenhil; S. Oerlemans; M. Eurelings; M. C. Minnema; C. M. Eeltink; L. V. van de Poll-Franse; F. Mols

doi:10.1007/s00520-015-3032-y

Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice

A. J. M. Beijers^*, G. Vreugdenhil, S. Oerlemans, M. Eurelings, M. C. Minnema, C. M. Eeltink, L. V. van de Poll-Franse, F. Mols

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma (MM) patients’ health-related quality of life (HRQOL). Dose modification is the only way to minimize CIPN. To measure CIPN in daily practice, the Indication for Common Toxicity Criteria (CTC) Grading of Peripheral Neuropathy Questionnaire (ICPNQ) was developed which can be completed within five minutes by the patient. The aims of this study were to (1) perform a psychometric evaluation of the ICPNQ and (2) examine the prevalence of CIPN and its influence on HRQOL in population-based MM patients.
Methods One hundred fifty-six MM patients, diagnosed between 2000 and 2014, completed the ICPNQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20), and EORTC QLQ-C30 (65 % response).
Results The psychometric analyses showed a Cronbach’s alpha of 0.84, 0.74, and 0.61 for, respectively, the sensory, motoric, and autonomic subscales of the ICPNQ. Test-retest reliability and construct validity were good for all subscales. Overall, 65 % of patients reported grade 2–3 neuropathy according to the ICPNQ. Patients with the highest CTC grades (grade 2 with neuropathic pain and grade 3 (38 %)) according to the ICPNQ reported significantly worse scores on all EORTC QLQ-CIPN20 subscales compared to patients with lower CTC grades (p ≤ 0.002). In addition, they reported statistically significant and clinically relevant worse HRQOL scores on almost all EORTC QLQ-C30 subscales.
Conclusions CIPN is a common side effect in MM patients, which has a negative impact on HRQOL. The ICPNQ is a valid instrument to distinguish the highest CIPN CTC grades from the lower CTC grades necessary to decide on dose modifications of chemotherapy in daily clinical practice.

Original language	English
Pages (from-to)	2411-2420
Number of pages	10
Journal	Supportive Care in Cancer
Volume	24
Issue number	6
DOIs	https://doi.org/10.1007/s00520-015-3032-y
Publication status	Published - Jun 2016

Keywords

Chemotherapy-induced peripheral neuropathy
Health-related quality of life
Indication for CTC Grading of Peripheral Neuropathy Questionnaire
Multiple myeloma
Patient-reported questionnaire
Validation

Access to Document

10.1007/s00520-015-3032-y

Cite this

Beijers, A. J. M., Vreugdenhil, G., Oerlemans, S., Eurelings, M., Minnema, M. C., Eeltink, C. M., van de Poll-Franse, L. V., & Mols, F. (2016). Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Supportive Care in Cancer, 24(6), 2411-2420. https://doi.org/10.1007/s00520-015-3032-y

@article{39b418fd3bed4a6c8e3eca2a33aa5e07,

title = "Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice",

abstract = "Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma (MM) patients{\textquoteright} health-related quality of life (HRQOL). Dose modification is the only way to minimize CIPN. To measure CIPN in daily practice, the Indication for Common Toxicity Criteria (CTC) Grading of Peripheral Neuropathy Questionnaire (ICPNQ) was developed which can be completed within five minutes by the patient. The aims of this study were to (1) perform a psychometric evaluation of the ICPNQ and (2) examine the prevalence of CIPN and its influence on HRQOL in population-based MM patients.Methods One hundred fifty-six MM patients, diagnosed between 2000 and 2014, completed the ICPNQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20), and EORTC QLQ-C30 (65 % response).Results The psychometric analyses showed a Cronbach{\textquoteright}s alpha of 0.84, 0.74, and 0.61 for, respectively, the sensory, motoric, and autonomic subscales of the ICPNQ. Test-retest reliability and construct validity were good for all subscales. Overall, 65 % of patients reported grade 2–3 neuropathy according to the ICPNQ. Patients with the highest CTC grades (grade 2 with neuropathic pain and grade 3 (38 %)) according to the ICPNQ reported significantly worse scores on all EORTC QLQ-CIPN20 subscales compared to patients with lower CTC grades (p ≤ 0.002). In addition, they reported statistically significant and clinically relevant worse HRQOL scores on almost all EORTC QLQ-C30 subscales.Conclusions CIPN is a common side effect in MM patients, which has a negative impact on HRQOL. The ICPNQ is a valid instrument to distinguish the highest CIPN CTC grades from the lower CTC grades necessary to decide on dose modifications of chemotherapy in daily clinical practice.",

keywords = "Chemotherapy-induced peripheral neuropathy, Health-related quality of life, Indication for CTC Grading of Peripheral Neuropathy Questionnaire, Multiple myeloma, Patient-reported questionnaire, Validation",

author = "Beijers, {A. J. M.} and G. Vreugdenhil and S. Oerlemans and M. Eurelings and Minnema, {M. C.} and Eeltink, {C. M.} and {van de Poll-Franse}, {L. V.} and F. Mols",

year = "2016",

month = jun,

doi = "10.1007/s00520-015-3032-y",

language = "English",

volume = "24",

pages = "2411--2420",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer, Cham",

number = "6",

}

Beijers, AJM, Vreugdenhil, G, Oerlemans, S, Eurelings, M, Minnema, MC, Eeltink, CM, van de Poll-Franse, LV & Mols, F 2016, 'Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice', Supportive Care in Cancer, vol. 24, no. 6, pp. 2411-2420. https://doi.org/10.1007/s00520-015-3032-y

Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. / Beijers, A. J. M.; Vreugdenhil, G.; Oerlemans, S. et al.
In: Supportive Care in Cancer, Vol. 24, No. 6, 06.2016, p. 2411-2420.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Chemotherapy-induced neuropathy in multiple myeloma

T2 - influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice

AU - Beijers, A. J. M.

AU - Vreugdenhil, G.

AU - Oerlemans, S.

AU - Eurelings, M.

AU - Minnema, M. C.

AU - Eeltink, C. M.

AU - van de Poll-Franse, L. V.

AU - Mols, F.

PY - 2016/6

Y1 - 2016/6

N2 - Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma (MM) patients’ health-related quality of life (HRQOL). Dose modification is the only way to minimize CIPN. To measure CIPN in daily practice, the Indication for Common Toxicity Criteria (CTC) Grading of Peripheral Neuropathy Questionnaire (ICPNQ) was developed which can be completed within five minutes by the patient. The aims of this study were to (1) perform a psychometric evaluation of the ICPNQ and (2) examine the prevalence of CIPN and its influence on HRQOL in population-based MM patients.Methods One hundred fifty-six MM patients, diagnosed between 2000 and 2014, completed the ICPNQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20), and EORTC QLQ-C30 (65 % response).Results The psychometric analyses showed a Cronbach’s alpha of 0.84, 0.74, and 0.61 for, respectively, the sensory, motoric, and autonomic subscales of the ICPNQ. Test-retest reliability and construct validity were good for all subscales. Overall, 65 % of patients reported grade 2–3 neuropathy according to the ICPNQ. Patients with the highest CTC grades (grade 2 with neuropathic pain and grade 3 (38 %)) according to the ICPNQ reported significantly worse scores on all EORTC QLQ-CIPN20 subscales compared to patients with lower CTC grades (p ≤ 0.002). In addition, they reported statistically significant and clinically relevant worse HRQOL scores on almost all EORTC QLQ-C30 subscales.Conclusions CIPN is a common side effect in MM patients, which has a negative impact on HRQOL. The ICPNQ is a valid instrument to distinguish the highest CIPN CTC grades from the lower CTC grades necessary to decide on dose modifications of chemotherapy in daily clinical practice.

AB - Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma (MM) patients’ health-related quality of life (HRQOL). Dose modification is the only way to minimize CIPN. To measure CIPN in daily practice, the Indication for Common Toxicity Criteria (CTC) Grading of Peripheral Neuropathy Questionnaire (ICPNQ) was developed which can be completed within five minutes by the patient. The aims of this study were to (1) perform a psychometric evaluation of the ICPNQ and (2) examine the prevalence of CIPN and its influence on HRQOL in population-based MM patients.Methods One hundred fifty-six MM patients, diagnosed between 2000 and 2014, completed the ICPNQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20), and EORTC QLQ-C30 (65 % response).Results The psychometric analyses showed a Cronbach’s alpha of 0.84, 0.74, and 0.61 for, respectively, the sensory, motoric, and autonomic subscales of the ICPNQ. Test-retest reliability and construct validity were good for all subscales. Overall, 65 % of patients reported grade 2–3 neuropathy according to the ICPNQ. Patients with the highest CTC grades (grade 2 with neuropathic pain and grade 3 (38 %)) according to the ICPNQ reported significantly worse scores on all EORTC QLQ-CIPN20 subscales compared to patients with lower CTC grades (p ≤ 0.002). In addition, they reported statistically significant and clinically relevant worse HRQOL scores on almost all EORTC QLQ-C30 subscales.Conclusions CIPN is a common side effect in MM patients, which has a negative impact on HRQOL. The ICPNQ is a valid instrument to distinguish the highest CIPN CTC grades from the lower CTC grades necessary to decide on dose modifications of chemotherapy in daily clinical practice.

KW - Chemotherapy-induced peripheral neuropathy

KW - Health-related quality of life

KW - Indication for CTC Grading of Peripheral Neuropathy Questionnaire

KW - Multiple myeloma

KW - Patient-reported questionnaire

KW - Validation

U2 - 10.1007/s00520-015-3032-y

DO - 10.1007/s00520-015-3032-y

M3 - Article

C2 - 26634561

SN - 0941-4355

VL - 24

SP - 2411

EP - 2420

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 6

ER -